Telix Pharmaceuticals Limited announced a strategic merger with ITM Isotope Technologies Munich SE to create a vertically integrated radiopharmaceutical powerhouse. The transaction involves an upfront consideration of US$1.65 billion on a cash-free/debt-free basis, comprising approximately US$1.25 billion in Telix shares issued at US$11.841 per share and the assumption of US$302 million in net debt. Up to US$700 million in additional contingent consideration is tied to regulatory approvals and sales milestones for ITM-11, a late-stage therapeutic candidate for neuroendocrine tumors. The combined entity expects pro forma 2026 revenue exceeding US$1.3 billion. Telix Pharmaceuticals Limited operates in the radiopharmaceutical industry, developing targeted theranostics for cancer diagnosis and treatment.
